Quantcast
Last updated on April 16, 2014 at 5:23 EDT

Latest HspE7 Stories

2014-02-11 04:22:13

NORTH BRUNSWICK, N.J., Feb. 11, 2014 /PRNewswire/ -- PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia. The trial which is being conducted at three leading gynecological...

2013-12-11 08:30:47

BLUE BELL, Pa., Dec. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, has been invited to participate on an expert panel titled, Ovarian & Cervical Cancer - Evaluating the Role of Immunotherapy Exploring Three Approaches - Dendritic Cells, DNA Plasmids & Liposomal Delivery. Dr. Kim will discuss Inovio's DNA immunotherapy VGX-3100, which was designed to treat cervical pre-cancers and cancers, head...

2013-06-11 16:24:00

ALBUQUERQUE, N.M., June 11, 2013 /PRNewswire-USNewswire/ -- Only 15.5 percent of college students know that condoms don't fully protect a person from contacting the human papillomavirus, and this lack of knowledge can lead students to a false sense of security in their sexual practices, according to a new study in Radiologic Technology, a journal published by the American Society of Radiologic Technologists. Researchers at Texas State University surveyed freshman students to gauge their...

2012-12-04 04:21:53

RICHMOND, Va., Dec. 4, 2012 /PRNewswire/ -- Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective...

2012-11-27 04:21:09

SAN DIEGO, Calif., Nov. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) and the PIO XII Foundation, affiliated with Brazil's Barretos Cancer Hospital, today announced that they entered into a research collaboration to evaluate the performance of a urine-based molecular assay for detection of HPV types associated with cervical lesions. The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil's...

2012-07-20 01:48:35

Even though the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with throat cancer, say Henry Ford Hospital researchers. According to their new study, HPV has a substantial impact on overall survival in African Americans with oropharyngeal cancer, a cancer that affects part of the throat, the base of the tongue, the tonsils, the soft palate (back of the mouth),...

2012-06-19 09:35:08

Among patients with head and neck squamous cell carcinomas, a history of chronic inflammation in the mouth (periodontitis, i.e. gum disease) may be associated with an increased risk of tumors positive for human papillomavirus (HPV), according to a report published Online First by Archives of Otolaryngology — Head & Neck Surgery, a JAMA Network publication. The National Cancer Institute has reported a steady increase in the prevalence of oropharyngeal cancers in the United States...

2012-06-11 21:55:10

Researchers from Brigham and Women's Hospital uncover a population of cells that are targeted by the cancer-causing human papillomaviruses Virtually all cervical cancers are caused by HPV infections, with just two HPV types, 16 and 18, responsible for about 70 percent of all cases, according to the National Cancer Institute. Scientists have presumed for decades that the cervical cancers that develop from HPV infection arise in a specific location in the cervix. Now, new research from...

2012-01-23 08:00:00

LONDON, January 23, 2012 /PRNewswire/ -- Roche sets up co -marketing agreement with private laboratory to support greater access to HPV testing In an innovative commercial agreement, leading healthcare company Roche and foremost private cellular pathology laboratory Unilabs-IHS, are collaborating to help make state-of-the art testing for signs of cervical cancer more accessible to thousands of women in London and throughout the UK. Roche's leading-edge and fully...

2011-12-05 13:26:00

The Society Joins ABC News, United Nations Foundation's 'Million Moms Challenge' to Raise Awareness of Cervical Cancer Globally ATLANTA, Dec. 5, 2011 /PRNewswire-USNewswire/ -- Although largely preventable through early detection, cervical cancer is the leading cause of cancer death among women globally, especially in developing countries where more than 85 percent of the estimated 529,800 cervical cancer cases in 2008 occurred. While cervical cancer screening rates have decreased by as...